COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan ®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

CONCLUSIONS: YSLT eye drops demonstrated non-inferiority to latanoprost in reducing IOP. Both products were well tolerated without serious TEAEs reported.PMID:37674345 | DOI:10.1080/14740338.2023.2252341

Source: Expert Opinion on Drug Safety - September 7, 2023 Category: Drugs & Pharmacology Authors: Stylianos Kandarakis Alexandros P Papadopoulos Georgios Roussopoulos Eustathios Georgopoulos Youngsik Chung Leonidas Doumazos Areum Baek Nefeli Ioanna Paizi Hyunik Shin Pantelis A Papadopoulos Source Type: research